D
Ionis Pharmaceuticals, Inc. IONS
$81.84 $0.530.65% NASDAQ
Recommendation
Prev Close
$81.31
Volume
2,531,161
Avg Vol (90D)
2,649,157
Market Cap
$13.17B
Dividend & Yield
--
52-Week Range
$23.95 - $82.95
P/E (TTM)
--
EPS (TTM)
-$1.69
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS)
12/3/2025 - TipRanks Financial Blog
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week High - Still a Buy?
12/2/2025 - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Designation
12/2/2025 - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS)
12/2/2025 - GuruFocus
Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen
12/2/2025 - The Fly
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
12/2/2025 - Business Wire
Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock
12/2/2025 - 24/7 Wall St.
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen
12/1/2025 - Simply Wall St
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA)
12/1/2025 - TipRanks Financial Blog
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Olezarsen
12/1/2025 - GuruFocus
Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen
12/1/2025 - The Fly
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
12/1/2025 - Business Wire
Capital Counsel LLC NY Has $1.98 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS
12/1/2025 - MarketBeat
Swiss National Bank Buys 13,300 Shares of Ionis Pharmaceuticals, Inc. $IONS
11/30/2025 - MarketBeat
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 16,777 Shares of Stock
11/30/2025 - MarketBeat
Why Ionis Pharmaceuticals (IONS) Is Up 8.7% After Donidalorsen EMA Milestone and $700 Million Offering News
11/29/2025 - Simply Wall St
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 16,777 Shares
11/29/2025 - Ticker Report
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 16,777 Shares of Stock
11/29/2025 - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Groupama Asset Managment
11/29/2025 - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Brokerages
11/29/2025 - MarketBeat
Insider Sell: Shannon Devers Sells 16,777 Shares of Ionis Pharmaceuticals Inc (IONS)
11/29/2025 - GuruFocus
Edmond DE Rothschild Holding S.A. Buys 73,400 Shares of Ionis Pharmaceuticals, Inc. $IONS
11/27/2025 - MarketBeat
DNB Asset Management AS Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS
11/27/2025 - MarketBeat
Creative Planning Has $2.11 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
11/27/2025 - MarketBeat
Ionis Pharmaceuticals (IONS, $80.93) RSI Indicator left the overbought zone on November 25, 2025
11/26/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$966.96M
EBITDA (TTM)
-$266.80M
EBIT (TTM)
-$278.05M
Net Income (TTM)
-$256.34M
Balance Sheet
Total Assets (Q)
$3.03B
Total Debt (Q)
$2.06B
Total Liabilities (Q)
$2.42B
Book Value Per Share (Q)
$3.84
Cash Flow
Cash from Operations (TTM)
-$247.01M
Cash from Investing (TTM)
$209.94M
Cash from Financing (TTM)
$40.55M
Net Change in Cash (TTM)
$3.74M
Filings
Filing Date
Wednesday, October 29, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 16 and 20 (est)
Price History
Loading...
Beta
0.62
7-Day Total Return
7.56%
30-Day Total Return
14.24%
60-Day Total Return
27.08%
90-Day Total Return
98.79%
Year to Date Total Return
135.92%
1-Year Total Return
128.54%
2-Year Total Return
59.04%
3-Year Total Return
109.95%
5-Year Total Return
60.57%
52-week Low
Apr 09, 2025 - $23.95
52-week High
Nov 28, 2025 - $82.95
Valuation
Market Cap
$13.17B - Large Cap
Enterprise Value
$12.99B
Price/Sales (TTM)
13.43
Price/Book (Q)
21.20
Dividends and Shares
Shares Outstanding
159.77
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ionis.com
Phone Number
760 931 9200
Address
2855 Gazelle Court
Carlsbad, CA 92010
Country
United States
Year Founded
1989
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed